137Summarizing discussion

68. Schaftenaar E, van Gorp EC, Meenken C, et al. Ocular infections in sub-Saharan Africa in the context of high HIV prevalence. Trop Med Int Health 2014; 19: 1003-14.

69. Wells JM and Smith JR. Uveitis in human immunodeficiency virus-infected individuals. Int Ophthal-

mol Clin 2015; 55: 11-8.

70. Schaftenaar E, Meenken C, Baarsma GS, et al. Uveitis is predominantly of infectious origin in a high HIV and TB prevalence setting in rural South Africa. Br J Ophthalmol 2016.

71. Mwanza JC and Kayembe DL. Uveitis in HIV-infected patients. Eur J Ophthalmol 2001; 11: 53-6. 72. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995; 93: 623-83. 73. Pertel P, Hirschtick RE, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected

with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992; 5: 1069-74.

74. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunode- ficiency virus immunosuppression. Arch Ophthalmol 1996; 114: 821-7.

75. Moraes HV Jr. Ocular manifestations of HIV/AIDS. Curr Opin Ophthalmol 2002; 13: 397-403. 76. Nirwoth JP, Hall AB and Lewallen S. Prevalence of cytomegalovirus retinitis in Tanzanians with low

CD4 levels. Br J Ophthalmol 2011; 95: 460-2.

77. Basu S, Monira S, Modi RR, et al. Degree, duration, and causes of visual impairment in eyes affected with ocular tuberculosis. J Ophthalmic Inflamm Infect 2014; 4: 3.

78. Bodaghi B and LeHoang P. Ocular tuberculosis. Curr Opin Ophthalmol 2000; 11: 443-8. 79. Harper C. Tuberculosis, a neglected opportunity? Nat Med 2007; 13: 309-12.

80. Tabbara KF. Ocular tuberculosis: anterior segment. Int Ophthalmol Clin 2005; 45: 57-69.

81. Gupta V, Gupta A and Rao NA. Intraocular tuberculosis–an update. Surv Ophthalmol 2007; 52: 561-87.

82. Department of Health, Republic of South Africa, Pretoria, South Africa. National Tuberculosis Management Guidelines 2014. May 27, 2014. Available at: http://www.sahivsoc.org/upload/docu- ments/NTCPAdult_TB%20Guidelines%2027.5.2014.pdf.

83. Schaftenaar E, Meenken C, Baarsma GS, et al. Good visual outcome of tuberculous chorioretinitis after ART initiation in a HIV-infected patient. Int Ophthalmol 2014; 34: 1263-5.

84. Robinson MR, Ross ML and Whitcup SM. Ocular manifestations of HIV infection. Curr Opin Ophthal-

mol 1999; 10: 431-7.

85. Kiss S, Damico FM and Young LH. Ocular manifestations and treatment of syphilis. Semin Ophthal-

mol 2005; 20: 161-7.

86. Fonollosa A, Giralt J, Pelegrín L, et al. Ocular syphilis--back again: understanding recent increases in the incidence of ocular syphilitic disease. Ocul Immunol Inflamm 2009; 17: 207-12.

87. Rose-Nussbaumer J, Goldstein DA, Thorne JE, et al. Uveitis in human immunodeficiency virus- infected persons with CD4+ T-lymphocyte count over 200 cells/mL. Clin Experiment Ophthalmol 2014; 42: 118-25.

88. Woolston S, Cohen SE, Fanfair RN et al. A Cluster of Ocular Syphilis Cases – Seattle, Washington, and San Francisco, California, 2014-2015. MMWR Morb Mortal Wkly Rep 2015; 64: 1150-1.

89. Sahin O and Ziaei A. Clinical and laboratory characteristics of ocular syphilis, co-infection, and therapy response. Clin Ophthalmol 2015; 10: 13-28.

90. Margo CE and Hamed LM. Ocular syphilis. Surv Ophthalmol 1992; 37: 203-20.

91. Troutbeck R, Chhabra R and Jones NP. Polymerase chain reaction testing of vitreous in atypical ocular syphilis. Ocul Immunol Inflamm 2013; 21: 227-30.

92. Cornut PL, Sobas CR, Perard L, et al. Detection of Treponema pallidum in aqueous humor by real- time polymerase chain reaction. Ocul Immunol Inflamm 2011; 19: 127-8.

Chapter 8

138

93. Scheepers MA, Lecuona KA, Rogers G, et al. The value of routine polymerase chain reaction analysis of intraocular fluid specimens in the diagnosis of infectious posterior uveitis. ScientificWorldJournal 2013; 2013: 545149.

94. Rothova A, de Boer JH, Ten Dam-van Loon NH, et al. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. Ophthalmology 2008; 115: 306-11.

95. Harper TW, Miller D, Schiffman JC, et al. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol 2009; 147: 140-7.

96. Otiti-Sengeri J, Colebunders R, Kempen JH, et al. The Prevalence and Causes of Visual Loss Among HIV-Infected Individuals With Visual Loss in Uganda. J Acquir Immune Defic Syndr 2010; 53: 95-101. 97. Abu El-Asrar AM, Abouammoh M and Al-Mezaine HS. Tuberculous uveitis. Int Ophthalmol Clin 2010;

50: 19-39.

98. Vasconcelos-Santos DV, Zierhut M and Rao NA. Strengths and weaknesses of diagnostic tools for tuberculous uveitis. Ocul Immunol Inflamm 2009; 17: 351-5.

99. Wroblewski KJ, Hidayat AA, Neafie RC, et al. Ocular tuberculosis: a clinicopathologic and molecular study. Ophthalmology 2011; 118: 772-7.

100. Hunter RS and Lobo AM. Current diagnostic approaches to infectious anterior uveitis. Int Ophthal-

mol Clin 2011; 51: 145-56.

101. De Groot-Mijnes JD, Rothova A, Van Loon AM, et al. Polymerase chain reaction and Goldmann- Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J Ophthal-

mol 2006; 141: 313-8.

102. Danise A, Cinque P, Vergani S, et al. Use of polymerase chain reaction assays of aqueous humor in the differential diagnosis of retinitis in patients infected with human immunodeficiency virus. Clin

Infect Dis 1997; 24: 1100-6.

103. Cheung CM, Durrani OM and Murray PI. The safety of anterior chamber paracentesis in patients with uveitis. Br J Ophthalmol 2004; 88: 582-3.

104. Trivedi D, Denniston AK and Murray PI. Safety profile of anterior chamber paracentesis performed at the slit lamp. Clin Experiment Ophthalmol 2011; 39: 725-8.

105. Van der Lelij A and Rothova A. Diagnostic anterior chamber paracentesis in uveitis: a safe proce- dure? Br J Ophthalmol 1997; 81: 976-9.

106. Palmer JJ, Chinanayi F, Gilbert A, et al. Trends and implications for achieving VISION 2020 human resources for eye health targets in 16 countries of sub-Saharan Africa by the year 2020. Hum Resour

Health 2014; 12: 45.

107. De Smet MD, Taylor SRJ, Bodaghi B, et el. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011; 30: 452-70.

108. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.

109. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013; 10: e1001418. 110. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: An ambitious treatment target

to help end the AIDS epidemic. UNAIDS; 2014.

111. Jabs DA, Van Natta ML, Sezgin E, et al. Prevalence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 2015; 159: 1115-22.

139